PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40069439,Functional Activity and Binding Specificity of Small Ankyrin Repeat Proteins Called Ankyrons Against SARS-CoV-2 Variants.,2025,Yun-Jong Park; Wojciech Jankowski; Nicholas C Hurst; Jeremy W Fry; Nikolai F Schwabe; Linda C C Tan; Zuben E Sauna,"Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA.; Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA.; ProImmune Limited, Magdalen Centre, Oxford Science Park, Oxford, OX4 4GA, UK.; ProImmune Limited, Magdalen Centre, Oxford Science Park, Oxford, OX4 4GA, UK.; ProImmune Limited, Magdalen Centre, Oxford Science Park, Oxford, OX4 4GA, UK.; ProImmune Limited, Magdalen Centre, Oxford Science Park, Oxford, OX4 4GA, UK.; Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA. Zuben.Sauna@fda.hhs.gov.",N/A
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Wilhelmine Meeraus; Abigail Postema; Christen M Gray; Andrew Lee; Bárbara Emoingt Furtado; Eduardo Conde-Sousa; Mario Ouwens; Claudia Corte; Sylvia Taylor,"Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK. Electronic address: wilhelmine.meeraus@astrazeneca.com.; Formerly Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Real World Data Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Medical and Payor Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States.; Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Medical and Payor Statistics, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.; Formerly Evidence Generation, AstraZeneca, São Paulo, Brazil.; Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.",N/A
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Mary T Bausch-Jurken; Nicolas Van de Velde; Ekkehard Beck,"Moderna, Inc., Cambridge, MA, USA.; Moderna, Inc., Cambridge, MA, USA.; Moderna, Inc., Cambridge, MA, USA. Ekkehard.beck@modernatx.com.",N/A
40059831,Circulating neutralizing antibodies and SARS-CoV-2 variant replication following postvaccination infections.,2025,Miguel A Garcia-Knight; Amethyst Zhang,"Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.; Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.",N/A
